NYU Dataset

Immune Responses Observed Before and After BNT162b2 mRNA Vaccine Administration in Individuals with and without History of SARS-CoV-2 Infection

UID: 10529
* Corresponding Author
To study and compare longitudinal immune responses to two-dose BNT162b2 mRNA vaccinations, investigators recruited 15 adults with a history of laboratory-confirmed COVID-19 and 21 adults who did not have COVID-19. Participants' ages ranged from 21 to 65 years old. Peripheral immune responses were assessed via blood samples drawn before and after each vaccine dose. A total of five samples were collected from each participant: baseline, post first dose (6 to 13 days after the initial vaccination), pre second dose (immediately before the second vaccination and about 21 days since initial vaccination), post second dose (7 to 12 days after the second vaccination), and one month post second dose (about 4 weeks after the second vaccination). The investigators observed strong cytotoxic CD8+ T cell responses in both cohorts following receipt of the second vaccine dose. Progressive increases in humoral and antigen-specific antibody-secreting cell (ASC) responses were observed among SARS-CoV-2-naive individuals following each vaccine dose, but not among individuals with prior infection with SARS-CoV-2.
Geographic Coverage
New York (State) - New York City
Subject of Study
Subject Domain
Population Age
Adult (19 years - 64 years)
Senior (65 years - 79 years)


Free to All
The de-identified data underlying supplemental figures can be downloaded through PubMed Central (PMC) under Supplementary Materials.
Access via PMC

Data file

Access via Zenodo

Scripts for analyses in R

Associated Publications
Data Type
Software Used
rstatix v0.6.0
Study Type
Dataset Format(s)
Microsoft Excel
Grant Support
LF-OC-20-000351/LEO Foundation